New treatment tested for debilitating Muscle-Weakening disease
NCT ID NCT07246564
Summary
This study is testing an existing drug, rozanolixizumab, in Chinese adults with generalized myasthenia gravis (gMG), a disease that causes severe muscle weakness. The main goal is to see if the drug improves patients' ability to perform daily activities and reduces their muscle weakness symptoms over a 6-week treatment period. Researchers will also closely monitor the drug's safety in this specific patient group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mg0033 20040
RECRUITINGBeijing, China
-
Mg0033 20172
RECRUITINGShanghai, China
-
Mg0033 20184
RECRUITINGShenzhen, China
-
Mg0033 20185
RECRUITINGJinan, China
-
Mg0033 20204
RECRUITINGSuzhou, China
-
Mg0033 20295
RECRUITINGChangsha, China
-
Mg0033 20347
RECRUITINGJinan, China
-
Mg0033 20348
RECRUITINGFuzhou, China
-
Mg0033 20349
RECRUITINGXuzhou SHI, China
Conditions
Explore the condition pages connected to this study.